Literature DB >> 26231089

Attitudes to outcomes measured in clinical trials of cardiovascular prevention.

M Canavan1, A Smyth2, S M Robinson3, I Gibson3, C Costello4, S T O'Keeffe3, T Walsh3, E C Mulkerrin3, M J O'Donnell5.   

Abstract

BACKGROUND: Selecting outcome measures in cardiovascular prevention trials should be informed by their importance to selected populations. Major vascular event outcomes are usually prioritized in these trials with considerably less attention paid to cognitive and functional outcomes. AIM: To examine views on importance of outcome measures used in clinical trials.
DESIGN: Cross-sectional survey.
METHODS: Of 367 individuals approached, 280 (76%) participated: outpatients attending cardiovascular prevention clinics (n = 97), active retirement groups members (n = 75), medical students (n = 108). Participants were asked to rank, in order of importance, outcome measures, which may be included in cardiovascular prevention trials. Results were compared between two groups: <65s (n = 157) and ≥65s (n = 104).
RESULTS: When asked what outcomes were most important to measure in cardiovascular prevention trials, respondents reported: death (31.6%) stroke (28.5%), dementia (26.9%), myocardial infarction (MI) (7.9%) and requiring nursing home (NH) care (5.1%). When asked the most relevant outcomes regarding successful ageing respondents reported; maintaining independence (32.4%), avoiding major illness (24.3%), good family life (23.6%), living as long as possible (15.8%), avoiding NH care (3.1%) and contributing to society (0.8%) as most important. When asked what outcome concerned them most about the future, respondents reported: dementia (32.6%), dependence (30.4%), death (12.8%), stroke (12.5%), cancer (6.2%) requiring NH care (4.8%) and MI (0.7%). Maintaining independence was considered most important in younger and older cohorts.
CONCLUSION: Cognitive and functional outcomes are important patient-relevant outcomes, sometimes more important than major vascular events. Incorporating these outcomes into trials may encourage patient participation and adherence to preventative regimens.
© The Author 2015. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2015        PMID: 26231089     DOI: 10.1093/qjmed/hcv132

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  4 in total

1.  Tailoring lipid management interventions to reduce inequalities in cardiovascular disease risk management in primary care for deprived communities in Northern England: a mixed-methods intervention development protocol.

Authors:  Yu Fu; Eugene Yh Tang; Sarah Sowden; Julia L Newton; Paula Whitty
Journal:  BMJ Open       Date:  2022-07-04       Impact factor: 3.006

2.  Development of the International Cardiac Rehabilitation Registry Including Variable Selection and Definition Process.

Authors:  Mohiul I Chowdhury; Karam Turk-Adawi; Abraham Samuel Babu; Gabriela Lime de Melo Ghisi; Pamela Seron; Tee Joo Yeo; Jamal Uddin; Martin Heine; Marianna Garcia Saldivia; Evangelia Kouidi; Masoumeh Sadeghi; Raghdah Aljehani; Sherry L Grace
Journal:  Glob Heart       Date:  2022-01-11

3.  Are large simple trials for dementia prevention possible?

Authors:  William N Whiteley; Sonia Anand; Shrikant I Bangdiwala; Jackie Bosch; Michelle Canavan; Howard Chertkow; Hertzel C Gerstein; Philip Gorelick; Martin O'Donnell; Guillaume Paré; Marie Pigeyre; Sudha Seshadri; Mike Sharma; Eric E Smith; Jeff Williamson; Tali Cukierman-Yaffe; Robert G Hart; Salim Yusuf
Journal:  Age Ageing       Date:  2020-02-27       Impact factor: 10.668

4.  Challenges Conveying Clinical Equipoise and Exploring Patient Treatment Preferences in an Oncology Trial Comparing Active Monitoring with Radiotherapy (ROAM/EORTC 1308).

Authors:  Frances C Sherratt; Stephen L Brown; Brian J Haylock; Priya Francis; Helen Hickey; Carrol Gamble; Michael D Jenkinson; Bridget Young
Journal:  Oncologist       Date:  2020-02-11       Impact factor: 5.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.